New reporting describes mixed sexual changes during GLP-1 treatment. Learn how the evidence differs and what to discuss with a prescriber.
On October 22, 2026, Men’s Health published a report on GLP-1 medicines and sexual health. Updated October 24, it brought together individual accounts of changes in libido and orgasm with research on sexual function. The experiences described moved in different directions.
For adults noticing a change during treatment, that mixed picture raises a reasonable question: what deserves attention, and what does the research actually establish? The reporting points toward a specific conversation with the prescriber rather than a simple conclusion about hormones.
Understanding the update starts with separating the different sexual experiences being discussed and the different kinds of evidence behind them.
This was a reporting update, not the publication of one new clinical trial. Men’s Health assembled personal accounts alongside survey findings and studies of particular medicines. Those sources answer different questions.
The report cited a 2025 Kinsey Institute survey of GLP-1 users. It described respondents’ experiences of desire and sexual function, but the article did not provide the survey’s exact sample size. The percentages therefore need to remain attached to that survey rather than being presented as the expected experience of everyone taking these medicines.
The article also discussed a 2025 observational study involving semaglutide. Its outcomes included new erectile-dysfunction diagnoses or prescriptions. Separate research involving dulaglutide included a four-week study of desire and a longer-term study of erectile dysfunction.
These differences matter before any results are compared. A report about sexual interest is not measuring the same outcome as a medical record showing an erectile-dysfunction diagnosis. Neither automatically describes what happens with orgasm.
The 2025 Kinsey Institute survey, as reported by Men’s Health, included both positive and negative experiences among GLP-1 users:
These figures describe separate reported outcomes. An increase in sexual interest should not be read as evidence of improved erections or a change in orgasm. Likewise, a report of lower desire does not identify which part of someone’s sexual experience has changed.
The useful finding is the variation itself. The survey does not support a single story in which everyone becomes more interested in sex or everyone becomes less interested.
According to Men’s Health, the 2025 observational study found that semaglutide users were more likely to receive a new erectile-dysfunction diagnosis or prescription.
The dulaglutide findings pointed elsewhere. The four-week study found no effect on desire. A separate longer-term study associated dulaglutide use with a slightly lower risk of moderate-to-severe erectile dysfunction.
Those results should remain separate. Different medicines and different outcomes do not form one interchangeable finding about “sexual function.”
The report also described a 2025 analysis of FDA adverse-event reports that identified orgasm-related complaints. This adds another outcome to the discussion rather than simply repeating the findings about desire or erections.
For readers, the distinction is practical. “My sexual experience has changed” is a valid starting point. Describing the particular change makes the concern clearer.
The strongest limitation is the design of the evidence. The semaglutide study was observational, so its association does not show that the medicine caused the diagnoses or prescriptions. The survey percentages are self-reports rather than clinical-trial estimates of the likelihood of a medication-caused change.
FDA adverse-event reports have a different limitation. They can identify concerns that deserve investigation, but they cannot establish causation or show how often a complaint occurs among all users.
Study size and funding also affect interpretation. Men’s Health noted that the short dulaglutide study was small. It flagged industry funding for the longer-term study, which is relevant when weighing its findings.
Cardiologist Evan Appelbaum told the publication that prospective studies are needed to separate direct medication effects from the changes that accompany treatment. Designs suited to answering that question largely do not yet exist. Weight loss and pre-existing sexual difficulties are among the factors that complicate the comparison.
There are also limits to applying findings across people and medicines. The reporting includes male sexual-health evidence, but it does not establish equivalent effects across women and men or across age groups. Internist Jay Luthar cautioned against treating liraglutide and semaglutide findings as interchangeable with findings about tirzepatide.
Finally, proposed mechanisms remain unproven. The report discussed reward-related brain pathways, but animal findings do not establish the same effect on human sexual desire. Family and obesity medicine physician Marsha Novick said the literature does not demonstrate that these medicines are causing changes in desire or erectile dysfunction in the population under discussion.
The October reporting brought earlier findings into a broader public discussion. Read alongside the 2025 survey and observational study, it presents an unresolved question rather than a consistent treatment effect. The Spanish-language coverage of GLP-1 medicines and desire also describes mixed reports of sexual changes during treatment.
The clinicians interviewed by Men’s Health offered a wider framework for interpreting these experiences. They identified nausea and fatigue as possible influences. Low food intake, mood changes and disrupted sleep were also part of the discussion.
Other possible influences pointed in a different direction. Luthar suggested that weight loss and improved energy or confidence could be associated with greater interest in sex. Metabolic improvement and self-image were also among the explanations considered in the report.
This fits a broader way of thinking about sexual wellbeing: interest and physical function should be considered alongside the person’s overall circumstances. It is also a useful perspective when reading about sexual desire during midlife.
The practical distinction is between noticing a change and identifying its explanation. Someone’s experience deserves to be heard even when its cause remains uncertain. At the same time, the reporting provides no basis for treating a GLP-1 medicine as a treatment for low libido or another sexual-health concern.
The clinicians interviewed by Men’s Health recommend discussing bothersome sexual changes with the prescribing clinician. Their advice focuses on describing the experience and its timing rather than arriving with a presumed explanation.
A useful conversation can include the following details:
These details are context for clinical review, not a home test for proving a side effect. The purpose is to make the concern specific enough to discuss alongside the treatment’s intended benefits.
The reporting also advises against stopping or altering a prescribed medicine solely because of a suspected sexual side effect. Decisions about medication changes belong with the prescriber, who can weigh the symptom’s impact against the reasons for treatment. The available evidence does not support a general dose-adjustment approach for sexual concerns.
New erectile difficulties may call for a wider assessment rather than medication review alone. Clinicians quoted in the article noted possible connections with cardiovascular health or testosterone. They also mentioned thyroid issues and alcohol, alongside stress and relationship factors.
That is a reason to keep the clinical conversation broad, not to assume any of those explanations applies to an individual. Readers seeking more background can also read about the wider context of erectile changes in midlife. General education can clarify the questions while qualified care addresses the personal decisions.
There is no need to describe a sexual concern in technical language. A clear account of what feels different and why it matters is a useful starting point. The concern does not have to come with a ready-made explanation to deserve attention.
Sexual wellbeing belongs in the conversation, even before there is a clear answer.
Sexual changes during GLP-1 treatment raise questions that individual stories cannot settle, so Sexential keeps evidence and everyday context together. When libido or arousal feels different, its educational coverage helps adults aged 35 to 65 understand the range of possible influences without turning general information into personal medical advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
How movement fits sexual wellbeing, with evidence on erectile function and menopause plus practical options that respect ability and health needs.
Understand testosterone symptoms, blood test interpretation, SHBG and health context, with questions for a midlife clinical assessment.
ACOG's updated menopause guidance includes five nonmedication approaches for hot flashes, sleep and mood. Learn how to interpret the recommendations.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
